Additive effects of ulinastatin and docetaxel on growth of breast cancer xenograft in nude mice and expression of PGE2, IL-10, and IL-2 in primary breast cancer cells

Cancer Biotherapy and Radiopharmaceuticals

Volumn 27, Issue 4, 2012, Pages 252-258

  Zhong, Biao ^a   Shen, Hongyan ^a   Sun, Xin ^a   Wang, Hong ^a   Zhang, Yonghua ^a   Sun, Zhijun ^a  

^a THE SECOND AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

breast cancer; COX2; IL 10; IL 2; PGE2; ulinastatin

Indexed keywords

CYCLOOXYGENASE 2; DOCETAXEL; INTERLEUKIN 10; INTERLEUKIN 2; MESSENGER RNA; PROSTAGLANDIN E2; ULINASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; DOWN REGULATION; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CYCLOOXYGENASE 2; DINOPROSTONE; DOWN-REGULATION; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; GLYCOPROTEINS; HUMANS; INTERLEUKIN-10; INTERLEUKIN-2; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; RECEPTORS, PROSTAGLANDIN E, EP2 SUBTYPE; RNA, MESSENGER; TAXOIDS; TRYPSIN INHIBITORS; UP-REGULATION;

EID: 84862065964     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2011.1105     Document Type: Article

References (16)

1. Sheng H, Sun Z, Yu B. Expression of Th1/Th2 in breast cancer tissues and its significance. J Fourth Military Medical Univ 2007;28: 1899.
2. Zhao X, Sun X, Gao F, et al. Effects of ulinastatin and docataxel on breast tumor growth and expression of illustrate IL-6, IL-8, and TNF-a. J Exp Clin Cancer Res 2011;30: 22.
3. Sun ZJ, Yu T, Chen JS, et al. Effects of ulinastatin and cyclophosphamide on the growth of xenograft breast cancer and expression of CXC chemokine receptor and matrix metalloproteinase-9 in cancers. J Int Med Res 2010;38: 967.
4. Bullock K, Blacjwell K. Clinical efficacy of taxane-trastuzumab combination regiments for HER-2-prositive metastatic breast cancer. Oncologist 2008;13: 515.
5. Maihöfner C, Charalambous MP, Bhambra U, et al. Expression of cycloxygenase-2 parallels expression of interleukin-1 beta, interleukin-6 and NF-kappa B in human colorectal cancer. Carcinogenesis 2003;24: 665.
6. Dannenberg AJ, Altorki NK, Boyle JO, et al. Cyclcoxygenase- 2: Apharmacological target for the prevention of cancer. Lancet Oncol 2001;2: 544.
7. Howe LR. Cyclooxygenase/prostaglandin signaling and breast cancer. Breast Cancer Res 2007;9: 210.
8. Grover JK, Yadav S, Vats V, et al. Cyclooxygenase 2 inhibitors: Emerging roles in the gut. Int J Colorectal Dis 2003; 18: 279.
9. Silverman DG, Halaszynski T, Sinatra R, et al. Rofecoxib does not compromise platelet aggregation during anesthesia and surgery. Can J Anaesth 2003;50: 1004.
10. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352: 1092.
11. Solomon SD, McMurray JJ, Pfeffer MA, et al. Adenoma Prevention with Celecoxib (APC) Study Investigators: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 1071.
12. Barnes NL, Warnberg F, Farnie G, et al. Cyclooxygenase-1 inhibition: Effects on tumour growth, cell cycling and lymphangiogenesis in a xenograft model of breast cancer. Br JCancer 2007;96: 575.
13. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX2 inhibitors. JAMA 2001;286: 954.
14. Wong BC, Jiang XH, Lin MC, et al. Cyclooxygenase-2 inhibitor (SC-236) suppresses activator protein-1 through c-jun NH2-terminal kinase. Gastroenterology 2004;126: 136.
15. Harris SG, Padilla J, Koumas L, et al. Prostaglandins as modulators of immunity. Trends Immunol 2002;23: 144.
16. Yang L, Yamagata N, Yadav R, et al. Cancer-associated immunodeficiency and endritic cell abnormalities mediated by the prostaglandin EP2 receptor. J Clin Invest 2003;111: 727.